“Bugs as Better Drugs: Leveraging Biofilms for Better Live Bacterial Therapeutics”

INDIANAPOLIS–(BUSINESS WIRE)–Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced that it will present at the Microbiome Movement – Drug Development Summit on June 22nd at The Seaport Hotel and World Trade Center in Boston.

Scioto presents “Bugs as Better Drugs: Leveraging Biofilms for Better Live Bacterial Therapeutics” at #Microbiome Movement – Drug Development Summit in Boston

Tweet this

Joe Trebley, Chief Executive Officer of Scioto will give a talk titled “Bugs as Better Drugs: Leveraging Biofilms for Better Live Bacterial Therapeutics,” which will highlight the company’s unique live bacterial therapeutic platform formulation (SB-121). By delivering live bacteria in the biofilm state, the SB-121 platform promotes colonization and provides lasting beneficial effects. Studies in premature animals have shown the ability to alter the microbiome with just a single dose of bacteria.

“Our novel platform provides enhanced function and persistent live bacterial therapeutics. This will be a tremendous benefit to patients,” explained Trebley. “We can take an off-the-shelf commensal bacteria and create a pipeline of live bacterial therapeutics.”

The Microbiome Movement – Drug Development Summit is the industry leading forum that focuses exclusively on the development and commercialization of microbiome-based therapeutics; with case-studies from target discovery all the way through to clinical trial development, manufacturing and beyond.

About Scioto Biosciences

Based in Indianapolis, Scioto Biosciences is a preclinical stage company developing innovative therapies devoted to having a transformative impacton the delivery of live bacterial therapeutics (LBTs). Scioto was founded in 2017 as a partnership between Indiana business accelerator, Monon Bioventures (MBCV) and The Research Institute at Nationwide Children’s Hospital (RINCH), with whom the company has a worldwide exclusive licensing agreement. The Scioto Platform has the potential to enhance efficacy wherever LBTs are used such as diabetes, neurological disorders, gastrointestinal health, alternatives to in-feed antibiotics (in livestock) and others. For more information, visit http://sciotobiosciences.com/.